H.R. 4231 · 119th Congress · Health

Treat and Reduce Obesity Act of 2025

In committee808 words Introduced Jun 27, 2025 · Latest action Jun 27, 2025

How far it has goneStage 2 of 6
  1. IntroducedJun 27, 2025 Done
  2. CommitteeReferred to 2 committees Current stage
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill expands Medicare coverage of intensive behavioral therapy for obesity. Specifically, the bill allows coverage for therapy that is provided by (1) a physician who is not a primary care physician; or (2) other health care providers (e.g., physician assistants and nurse practitioners) and approved counseling programs, if provided upon a referral from, and in coordination with, a physician or primary care practitioner. Currently, such therapy is covered only if provided by a primary care practitioner.

The bill also allows coverage under Medicare's prescription drug benefit of drugs used for the treatment of obesity or for weight loss management for individuals who are overweight.

Congressional Research Service · summary of “Introduced in House” version · Jun 27, 2025

Who lobbies on it

8 organizations · 28 filings · Q2 2025–Q3 2026

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Academy of Nutrition and Dietetics (formerly As American Dietetic Association) 6 of 6 quarters
    “Medical Nutrition Therapy Act (H.R.6199; S.3934) Expanding Access to Diabetes Self-Management Training Act (H.R.3826, S.1925) Treat and Reduce Obesity Act (H.R.4231/S.1973) Medically Tailored Home-Delivered Meals Demonstration Pilot Act (HR.5753, S.2834) CONNECT for Health Act (H.R. 4206/S. 1261)”

    Q3 2026 filing · $411K lobbying spend in 2026 to date, all issues

  2. America's Health Insurance Plans Inc (ahip) 5 of 6 quarters
    “H.R. 1 - One Big Beautiful Bill Act - Rep. Arrington, Jodey - Medicaid eligibility and state financing, Marketplace coverage and enrollment, Health Savings Account expansion, Pharmacy Benefit Manager financing and regulation H.R. 843 - Prompt Approval of Safe Generic Drugs Act - Rep. Barragan, Nanette Diaz - Generic…”

    Q3 2026 filing · $11.3M lobbying spend in 2026 to date, all issues

  3. Eli Lilly and Company Fka Lilly Usa, Llc 5 of 6 quarters
    “Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage…”

    Q3 2026 filing · $9.6M lobbying spend in 2026 to date, all issues

5 more organizations, every filingPROUpgrade

Organizations that named H.R. 4231 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.

Actions

2 actions · newest first
  1. Jun 27, 2025Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  2. Jun 27, 2025Introduced in House